Meningococcal Infections Completed Phase 3 Trials for Meningococcal polysaccharide vaccine group Y (DB13888)

Also known as: Infections, Meningococcal / Meningococcal Infection / Meningococcal disease / Unspecified meningococcal infection / Meningococcal infection, unspecified / Neisseria meningitidis infection NOS

DBCOND0032814 (Meningococcal Infections)Completed3 IdentifierTitlePurposeDrugs
NCT02986854Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY VaccinationPrevention
NCT00474266Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old ChildrenPrevention
NCT00674583Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy ChildrenPrevention
NCT01144663Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib VaccinesPrevention
NCT01266993Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy ChildrenPrevention
NCT00614614Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014Prevention
NCT02106390Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy InfantsPrevention
NCT01755689Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsPrevention
NCT00465816Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612Prevention
NCT00514904Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old SubjectsPrevention
NCT01767376Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of AgePrevention
NCT02955797Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in ToddlersPrevention
NCT03077438Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 YearsPrevention
NCT00616421Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy ChildrenPrevention
NCT00359983Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIBPrevention